5241642026-09-095241642026-09-09in-capmkt:AdoptionOfNewLinesOfBusinessMember5241642026-09-09in-capmkt:ArrangementsForStrategicOrTechnicalOrManufacturingOrMarketingTieUpMemberiso4217:INRIOLCPIOL Chemicals and Pharmaceuticals Limited524164NOTLISTEDINE485C01029Arrangement/Adoption of new line/Closure of operations (Sub-para 2-Para B)Adoption of new line(s) of businessArrangements for strategic, technical, manufacturing, or marketing tie upNewfalse2026-09-0914:30:002026-09-09AgreementA leading global chemical companyLong-term manufacturing and supply of specialty chemicalsInternationalNot ApplicableManufacturing and supply of Specialty Chemicals (the “Product”) by the Company for the customer in accordance with the agreed terms.The arrangement is expected to contribute materially to the Company’s revenue stream upon commencement of commercial suppliesThe Company will manufacture and supply the Product exclusively for the customer in accordance with the mutually agreed terms. In view of the confidentiality obligations agreed between the parties, the Company is restricted from disclosing the identity of the customer and quantitative/commercial details of the arrangement. The estimated capital expenditure for establishing a dedicated manufacturing facility for the Product is approximately ₹35 Crore, which is proposed to be funded through the Company’s internal accruals.falseNot ApplicableIt is expected to provide a stable and reliable long-term demand for the Product, strengthen the Company’s manufacturing capabilities and expand its presence in the specialty chemicals and contract manufacturing segment for sustainable long-term growth of the CompanyContract Development and Manufacturing Organisation (“CDMO”) for Pharmaceutical FormulationsThe new line of business is primarily established to cater to the evolving and long-term contract manufacturing requirements of the Company’s Anchor Customers in the European region, leveraging the Company’s existing manufacturing capabilities, quality standards, regulatory compliance and technical expertise. The initiative is expected to strengthen long-term customer relationships, diversify the Company’s business portfolio and create additional opportunities across the pharmaceutical value chain.1100000000